{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:10:47Z","timestamp":1794975047930,"version":"4.9.1"},"reference-count":37,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Centre for Precision Cell Therapy for the Liver","award":["PMAS\/21\/07"],"award-info":[{"award-number":["PMAS\/21\/07"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Clinical Toxicology"],"published-print":{"date-parts":[[2023,8,3]]},"DOI":"10.1080\/15563650.2023.2259089","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T06:56:19Z","timestamp":1695884179000},"page":"567-572","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Novel biomarkers for drug-induced liver injury"],"prefix":"10.1080","volume":"61","author":[{"given":"Christopher","family":"Humphries","sequence":"first","affiliation":[{"name":"Pharmacology, Toxicology and Therapeutics, Centre for Cardiovascular Sciences, University of Edinburgh, The Queens Medical Research Institute, Edinburgh, UK"},{"name":"Centre for Precision Cell Therapy for the Liver, Lothian Health Board, Queens Medical Research Institute, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Dear","sequence":"additional","affiliation":[{"name":"Pharmacology, Toxicology and Therapeutics, Centre for Cardiovascular Sciences, University of Edinburgh, The Queens Medical Research Institute, Edinburgh, UK"},{"name":"Centre for Precision Cell Therapy for the Liver, Lothian Health Board, Queens Medical Research Institute, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"Center for Drug Evaluation and Research. Drug-induced liver injury: premarketing clinical evaluation [Internet]. Silver Spring (MD): U.S. Food and Drug Administration (USFDA); 2009. [cited 2023 May 10]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation."},{"key":"e_1_3_2_3_1","unstructured":"FDA-NIH Biomarker Working Group. BEST (biomarkers EndpointS and other tools) resource (Internet). Silver Spring (MD): U.S. Food and Drug Administration (USFDA); 2016\u201320. Glossary. 2016 Jan 28. Updated 2020 Mar 3. (Webpage)"},{"key":"e_1_3_2_4_1","unstructured":"Council for International Organisations of Medical Sciences. Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting; 2020."},{"key":"e_1_3_2_5_1","unstructured":"Critical Path Institute (C-Path) Predictive Safety Testing Consortium\u2019s (PSTC) Hepatocyte Working Group (HWG). Qualification plan for glutamate dehydrogenase (GLDH) as a biomarker of drug induced liver injury in individuals with skeletal muscle degeneration; 2020."},{"key":"e_1_3_2_6_1","first-page":"817","article-title":"The past and present of serum aminotransferases and the future of liver injury biomarkers","volume":"15","author":"McGill MR.","year":"2016","unstructured":"McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016;15:817\u2013828.","journal-title":"EXCLI J"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.108"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2021-101886"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30266-2"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1177271920974652"},{"key":"e_1_3_2_11_1","unstructured":"Medicines and Healthcare products Regulatory Agency. In vitro diagnostic medical devices: guidance on legislation [Internet]. 2020. [cited 2023 May 10]. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/946260\/IVDD_legislation_guidance_-_PDF.pdf."},{"key":"e_1_3_2_12_1","unstructured":"https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/about-biomarkers-and-qualification#:\u223c:text=biomarker%20measurement%20method.- How%20are%20biomarkers%20qualified%20for%20drug%20development%3F develop%20a%20biomarker%20for%20qualification."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1382"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27206"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.564"},{"key":"e_1_3_2_16_1","first-page":"472","volume-title":"Goldfrank\u2019s toxicologic emergencies","author":"Hendrickson R","year":"2019","unstructured":"Hendrickson R, McKeown N, et\u00a0al. Acetaminophen. In: Nelson L, Howland M, Lewin N, editors. Goldfrank\u2019s toxicologic emergencies. 11th ed. New York (NY): McGraw-Hill Education; 2019. p. 472\u2013491.","edition":"11"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.45"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313369"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-12-200212170-00007"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.12.1363"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000052"},{"key":"e_1_3_2_22_1","unstructured":"Food and Drug Administration. Letter-of-support-for-drug-induced-liver-injury-(DILI)-biomarker(s)-7-25-16.pdf [Internet]. [cited 2023 May 11]. Available from: https:\/\/fda.report\/media\/99532\/Letter-of-Support-for-Drug-Induced-Liver-Injury-%28DILI%29-Biomarker%28s%29-7-25-16.pdf."},{"key":"e_1_3_2_23_1","unstructured":"European Medicines Agency. Retraction of the \u201cLetter of support for drug-induced liver injury (DILI) biomarker\u201d (EMA\/423870\/2016) [Internet]. [cited 2023 May 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/retraction-letter-support-drug-induced-liver-injury-dili-biomarker-ema\/423870\/2016_en.pdf."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.022"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03150-9"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfab003"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29802"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12684"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1571"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.053"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.004"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.07.013"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13878"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2022.07.813"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.33590\/emjcardiol\/20-00045"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw047"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000400"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.053546"}],"container-title":["Clinical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15563650.2023.2259089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T09:59:05Z","timestamp":1727258345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15563650.2023.2259089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,3]]}},"alternative-id":["10.1080\/15563650.2023.2259089"],"URL":"https:\/\/doi.org\/10.1080\/15563650.2023.2259089","relation":{},"ISSN":["1556-3650","1556-9519"],"issn-type":[{"value":"1556-3650","type":"print"},{"value":"1556-9519","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}